Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Activation

MYX.1 (MCRN-003) -- A Single Arm Phase II Study of High-Dose Weekly Carfilzomib plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma After 1-3 Prior Therapies -- was centrally activated March 29, 2016.

Centres wishing to participate on this trial should contact Gail McDonald, Study Coordinator, at gmcdonald@ctg.queensu.ca.

Please note that the MYX.1 website can not be accessed through our CCTG Clinical Trials Website. The trial website can be found at https://www.myelomacanadatrials.ca/.